drugset / Trial / NCT06899399

Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis

NCT06899399

Recruiting 982 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the safety and efficacy of endovascular stenting combined with optimal medical therapy versus optimal medical therapy alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery. The study plans to enroll 982 patients aged 40-80 years who have had no ipsilateral carotid artery-related neurological symptoms in the past six months and who have declined carotid endarterectomy. The primary endpoints include stroke, myocardial infarction, or death within 30 days post-procedure/enrollment, as well as the incidence of ipsilateral stroke from 30 days to one year post-procedure/enrollment. Secondary endpoints include procedural success rate, restenosis rate, changes in cognitive function, and others. The study results will provide high-level evidence-based medical evidence for the treatment selection of patients with asymptomatic carotid artery stenosis.

Timeline

Start
2024-10-18
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 75 mg
Comparator Aspirin Small molecule 325 mg
Comparator Clopidogrel Small molecule
Comparator Dipyridamole Other / unclassified